The LUTHEE trial (NCT03454763) is currently ongoing and actively enrolling patients; it is a Phase II randomized clinical trial that aims to compare the efficacy and safety of two different administration schedules of Lu-177 DOTATATE PRRT in patients with SSTR2-positive tumors, including neuroendocrine tumors and potentially ENB [16]. This evidence concerns the gene SSTR2 and neuroendocrine neoplasm.